Effects of chemotherapy on pelvic tumors measured by MRI
Author Information
Author(s): Lankester K J, Taylor N J, Stirling J J, Boxall J, D'Arcy J A, Leach M O, Rustin G J S, Padhani A R
Primary Institution: Mount Vernon Hospital
Hypothesis
Do cytotoxic agents cause significant acute reductions in DCE-MRI parameters in patients with gynaecological tumors?
Conclusion
The study found no significant changes in DCE-MRI parameters after chemotherapy, suggesting that any observed effects may be due to vascular disruptive agents rather than chemotherapy alone.
Supporting Evidence
- Dynamic contrast-enhanced MRI is increasingly used in clinical trials to evaluate tumor microcirculation.
- Significant reductions in DCE-MRI parameters are observed with vascular disruptive agents within 4–24 hours.
- The study included a reproducibility analysis on 20 patients to assess DCE-MRI parameter changes.
Takeaway
The study looked at how chemotherapy affects tumors using MRI, and it found that chemotherapy doesn't seem to change the blood flow in tumors right away.
Methodology
Dynamic contrast-enhanced MRI scans were performed on patients before and after chemotherapy to assess changes in tumor blood flow.
Limitations
The study had a small sample size and excluded data from patients with technical failures or who could not complete scans.
Participant Demographics
The study included 24 female patients with an average age of 56 years, primarily with gynaecological cancers.
Statistical Information
Confidence Interval
95% confidence intervals for change were –11.9 to +13.6% for Ktrans and ±8.8% for IAUGC.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website